|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.350 USD | +1.50% |
|
+7.14% | -25.82% |
| 07-22 | Alzamend Neuro, Inc. Reports Earnings Results for the Full Year Ended April 30, 2026 | CI |
| 07-21 | Alzamend Neuro, Inc. Auditor Raises 'Going Concern' Doubt | CI |
Company Valuation: Alzamend Neuro, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: April | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 94.88 | 53.05 | 4.882 | 4.362 | 4.337 | 6.373 |
| Change | - | -44.08% | -90.8% | -10.66% | -0.56% | 46.92% |
| Enterprise Value (EV) | 94.88 | 53.05 | 4.882 | 4.362 | 4.337 | 6.373 |
| Change | - | -44.08% | -90.8% | -10.66% | -0.56% | 46.92% |
| P/E | -7.29x | -3.65x | -0.48x | -0.52x | -0.43x | -0.51x |
| PBR | 7.3x | - | -1.85x | - | 6.62x | -0.51x |
| PEG | - | -0.51x | 0x | 0x | 0x | 0.45x |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -0.6x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.59x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -189 | -202.5 | -132.3 | -11.32 | -2.63 | -2.6 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - |
| EBITDA 1 | -7.907 | -11.26 | -8.931 | -4.121 | -7.949 | -10.7 |
| EBIT 1 | -12.32 | -14.87 | -9.938 | -4.497 | -8.767 | -10.8 |
| Net income 1 | -12.36 | -14.88 | -9.948 | -5.105 | -8.772 | -10.8 |
| Net Debt | - | - | - | - | - | - |
| Reference price 2 | 1,377.000 | 738.855 | 63.990 | 5.940 | 1.140 | 1.330 |
| Nbr of stocks (in thousands) | 68.9 | 71.8 | 76.3 | 734 | 3,805 | 4,792 |
| Announcement Date | 7/19/22 | 7/27/23 | 7/30/24 | 7/22/25 | 7/22/26 | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.51x | - | - | - | 6.37M | |
| 32.25x | 5.76x | 17.3x | 1.02% | 46.86B | |
| -23.62x | 354.58x | -21.66x | -.--% | 40.23B | |
| 48.91x | 4.94x | 31.87x | -.--% | 36.23B | |
| 25.32x | 2.8x | 12.1x | -.--% | 34.72B | |
| 27.42x | 8.04x | 20.17x | 0.41% | 27.89B | |
| 34.31x | 5.61x | 25.58x | -.--% | 16.79B | |
| 22.12x | 1.95x | 8.48x | 1.19% | 13.12B | |
| 23.43x | 1.87x | 11.34x | -.--% | 12.7B | |
| Average | 21.07x | 48.19x | 13.15x | 0.33% | 25.39B | |
| Weighted average by Cap. | 22.49x | 66.41x | 12.08x | 0.33% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ALZN Stock
- Valuation Alzamend Neuro, Inc.
Select your edition
All financial news and data tailored to specific country editions
